Johnson & Johnson announces new results from Phase 2 RedirecTT-1 study

Johnson & Johnson announced new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY, the first U.S. Food and Drug Administration-approved GPRC5D-directed bispecific antibody, and TECVAYLI, the first FDA-approved BCMA-directed bispecific antibody. The results show a high overall response rate with durability in patients with triple-class exposed relapsed/refractory multiple myeloma who have true extramedullary disease, EMD. EMD is defined as soft tissue/organ-associated plasmacytomas with no contact to bony structures as per International Myeloma Working Group criteria. RedirecTT-1 is the largest study dedicated to patients with EMD to date. These data were featured in a late-breaking oral presentation at the 2025 European Hematology Association Congress.
Confident Investing Starts Here:

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Buzz Feed

37 minutes ago

• Buzz Feed

Lizzo Talks About Using Ozempic For Weight Loss

There's no point in stressing out over speculation and rumors regarding Lizzo — she's an open book. On a June 19 episode of the Just Trish podcast, Lizzo admitted that she tried Ozempic and other GLP-1 drugs, which are used to regulate type 2 diabetes and obesity, at one point in her "weight release" journey. Over the years, the "Truth Hurts" singer has been rather forthcoming with her fitness journey, documenting it on social media and sharing her progress with her fanbase. "I tried everything," she told Trisha Paytas. "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same item." In the podcast, Lizzo shut down critics of Ozempic and GLP-1 drugs, noting that people are not "cheating" by using the products. "It's not easy," Lizzo said. "It's a drug to help somebody with something they're struggling with. I think people... it's their way of being fat phobic when you're telling someone they're cheating." "They tell people they're cheating by getting that weight loss surgery. I heard about that weight loss surgery. That shit sounds very hard actually. A lot people felt like they almost died on the table, and they got so sick after getting the weight loss surgery. That shits not easy." "I feel like people just like to make fun of fat people. Whether you're big or small or got small, they like to make fun of us," she said. Lizzo claimed that she started noticing different results when adding meat back into her diet. "What did it for me is it was not being vegan," she said. "Because when I was vegan, I was consuming a lot of fake meats, I was eating a lot of bread, I was eating a lot of rice and I had to eat a lot of it to stay full." In her opinion, the "fake sugar and weird shit" in processed foods was holding her back, causing her to eat 3,000 to 5,000 calories a day. "When I started actually eating whole foods and eating, like, beef and chicken and fish," she said, "I was actually full and not expanding my stomach by putting a lot of fake things in there that wasn't actually filling me up." "I feel like I worked really, really hard and I was intentional what I did with my body," she added. And that's that! Take that shame somewhere else because Lizzo doesn't play that. Watch the full episode of Lizzo on the Just Trish podcast here.

Yahoo

3 hours ago

• Yahoo

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

Investing in biotech penny stocks is fraught with volatility, regulatory hurdles, and uncertain clinical results. Penny stocks are companies that trade for less than $5 per share. However, for those with a high risk tolerance, these small-cap stocks can provide outsized returns, particularly when scientific breakthroughs or U.S. Food and Drug Administration (FDA) approvals result in explosive gains. With Wall Street analysts issuing 'Strong Buy' ratings on these two high-potential plays, let's dig in to see whether these growth stocks could deliver on their promises. With a market capitalization of $21 million, Ovid Therapeutics is a small clinical-stage biopharmaceutical company focused on developing treatments for rare neurological disorders. Ovid's business model is centered on central nervous system (CNS) disorders, which are a challenging therapeutic area. Its pipeline includes novel compounds in early- to mid-stage development that target epilepsy and other genetically based neurological disorders. OVID stock has fallen 67.6% year-to-date (YTD), compared to the S&P 500 Index's ($SPX) gain of 1.6%. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Ovid currently has no FDA-approved products on the market. However, Wall Street analysts have called OVID a "Strong Buy," with all six analysts covering the stock rating it as such. Still, the company has also received a delisting notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share. Ovid has until Aug. 11, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days. Ovid's pipeline is small in size but very targeted. The most closely watched candidate is OV329, a highly selective small-molecule inhibitor of GABA aminotransferase (GABA-AT). OV329 is intended to treat epilepsy that has not responded to previous treatments. In preclinical models, the candidate has shown promise in controlling seizures while causing fewer side effects than existing treatments such as vigabatrin. Ovid Therapeutics anticipates Phase 1 trial results in the third quarter of 2025. The company has a good chance of its stock ticking upwards if the Phase 1 topline results for OV329 turn out positive. Ovid's other candidate is OV350, a next-generation KCC2 modulator that is also being tested in a Phase 1 trial. The company generated $130,000 in revenue from royalty agreements during Q1. At the end of the quarter, its cash, equivalents, and marketable securities totaled $43 million. This gives the company an estimated runway through the second half of 2026. Ovid has received a 'Strong Buy' rating on Wall Street because of its rich pipeline of rare disease treatments. The stock may appeal to long-term aggressive investors who are comfortable with volatility and have a strong interest in innovative science. However, I believe investors should wait until Ovid either clears the $1 delisting threshold or proves its clinical strategy with positive results. Analysts have an average target price of $2.88 for the stock, which implies upside potential of 860% from current levels. The Street-high price estimate stands at $4 for OVID stock. With a market cap of $609 million, Nuvation Bio is a clinical-stage biotech company that develops targeted oncology treatments for challenging cancers with limited treatment options. However, it may soon release a revenue-generating product to the market this year. NUVB stock is down 27.7% YTD, compared to the overall market gain. Nuvation Bio's pipeline includes programs addressing a variety of oncology targets, including breast, ovarian, and lung cancer. Its pipeline currently consists of four core programs: taletrectinib (ROS1 inhibitor), NUV-1511 (drug-drug conjugate), safusidenib (brain-penetrant IDH1 inhibitor), and NUV-868 (BET inhibitor). Taletrectinib, Nuvation's lead candidate for the treatment of ROS1+ and advanced non-small cell lung cancer, has already been approved in China and the United States. The company hopes to begin commercializing taletrectinib in mid-2025. In March, the firm secured $250 million in non-dilutive financing from Sagard Healthcare Partners, as well as $150 million in royalty financing and $50 million in debt, subject to approval. Nuvation also has the option to secure an additional $50 million in debt until June 30, 2026 if it completes its first commercial sale in the United States. Safusidenib is currently in Phase 2 trials, and NUV-1511 is in Phase ½ trials. The company intends to provide updates for both during the second half of 2025. Nuvation ended Q1 with $461.7 million in cash, cash equivalents, and marketable securities. A favorable FDA decision could open up significant market opportunities for the company. Nuvation Bio's late-stage pipeline, strong cash position, and clear commercialization path make it an appealing biotech growth stock to buy right now. However, the company's ability to generate profits after commercialization may take years, making it an appropriate choice for those with a high risk tolerance and a longer investment horizon. Overall, Wall Street rates NUVB stock a 'Strong Buy.' Of the seven analysts covering the stock, six rate Nuvation as a 'Strong Buy' while one recommends a 'Moderate Buy" rating. The average price target of $7.17 suggests that NUVB stock could rally around 258% over the next 12 months. The high price estimate of $10 suggests a gain of 400% over current levels. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

Chicago Tribune

4 hours ago

• Chicago Tribune

Former EPA administrator, activists react to 'One Big Beautiful Bill'

As President Donald Trump touts a bill currently making its way through Congress as a win for the public, a former regional Environmental Protection Agency administrator is prepared to see devastating cuts to the office that could negatively impact human health. 'It's proposing severe cuts to both the scientific work that EPA's Office of Research and Development does and to the agency as a whole,' said Debra Shore, former administrator for EPA Region 5. 'It would severely reduce the agency's ability to fulfill its mission of protecting public health and the environment.' As the 'One Big Beautiful Bill' Act has passed the U.S. House of Representatives and moved to the Senate, activists nationwide have worried about the consequences. Shore said it's heartbreaking to see public servants at the EPA go through these cuts, especially as the administration tries to make the 'One Big Beautiful Bill' seem like a win. 'I have never worked with a group of such smart, devoted professionals who had a shared sense of mission as EPA employees,' Shore said. 'I know that's the case across the agency. … They could be working for far higher salaries in many cases, but they are dedicated to the foundational mission of the EPA, which is to protect public health and the environment.' On Tuesday and Wednesday, the EPA posted on Facebook, saying it 'delivers for all Americans.' 'One Big Beautiful Bill is putting American workers, taxpayers and families first,' the EPA's Tuesday post said. 'Under (Trump), the U.S. can unleash American energy while ensuring we have the cleanest air, land and water on (Earth).' The bill eliminates hundreds of billions of dollars in Green New Deal tax credits, repeals former President Joe Biden administration's electric vehicle mandates, and opens federal lands and waters to oil, gas, coal, geothermal and mineral leasing, according to the EPA's Tuesday post. According to the Wednesday post, the bill also 'streamlines onerous permitting processes,' refills the Strategic Petroleum reserve and 'delivers certainty to energy producers, saves and creates energy jobs, lowers energy costs for families.' A spokesperson for Sen. Todd Young, R-Indiana, provided a statement about the bill Friday. 'Senator Young continues to have conversations with his colleagues and stakeholders about improving the House-passed bill and addressing our nation's debt and deficit challenges,' said Leah Selk, spokesperson for Young. Representatives for Sen. Jim Banks, R-Indiana, did not respond to a request for comment Friday. Within the bill, the White House would also have the ability to cut federal agencies and reduce workforce, Shore said. 'This is just an utter abrogation of Congress' authority and power,' Shore said. 'It requires an annual report of planned reorganizational moves, and it also streamlines the ability of any future president to rebuild federal agencies because of some of the language in it.' Susan Thomas, director of policy and press for Just Transition Northwest Indiana, said it's concerning that EPA is treating the 'One Big Beautiful Bill' like a win, especially on social media platforms that are easily accessible. 'No one can take any information for granted anymore,' Thomas said. 'You must do your own research with trusted sources because the amount of greenwashing that's coming down is so dangerous. … This is becoming increasingly difficult, but it's more important than ever.' Thomas and Gary Advocates for Responsible Development board member Carolyn McCrady are both worried about the effects that environmental justice communities will face if the bill passes the Senate. McCrady expects public health to worsen as a result of EPA rollbacks. An October report from Industrious Labs found that most residents in Gary are in the top 10% of U.S. residents most at-risk for developing asthma and at-risk of low life expectancy. In 2020, Indiana had a lung cancer rate of 72.5 per 100,000 people, with Lake County as one of the state's counties with the highest cancer mortality rates, according to the American Lung Association. A 2016 JAMA Network report also found Gary as one of the top five U.S. cities with the lowest life expectancy at one point. 'I think people are going to be sicker faster,' McCrady said. 'I don't think people will be able to be served in the medical community in the same way, because in Indiana, millions of people are going to lose their health insurance because of the Medicaid cuts.' Although McCrady believes the EPA cuts are devastating, she isn't surprised to see them included in 'One Big Beautiful Bill.' Cuts will continue to put communities like Gary at a greater disadvantage, McCrady said. Thomas also believes that Northwest Indiana's environmental justice communities will struggle as a result of the 'One Big Beautiful Bill.' 'They've already stripped away all of the environmental justice provisions that had taken years to recognize and acknowledge and to start to put in place,' Thomas said. 'This is just a very sad state that we're in.'